Company intelligence / Profile preview

Stratosvir

Stevenage, England, United Kingdomstratosvir.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Stratosvir is developing viral immunotherapy candidates at the preclinical stage. The company recently shipped its first products to an undisclosed partner for in vitro and in vivo testing. They expect to enter clinical testing by the end of 2025.[1]

Therapeutic areas: Oncology
Modalities: Viral immunotherapyoncolytic viruses (vaccinia viruses)
Industry: Biotech

Partnerships

Undisclosed partner for in vitro and in vivo testing[1]

Beyond the preview

Go deeper on Stratosvir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stratosvir.

Explore the full profile